Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease
American Journal of Hematology, Volume 88, No. 11, Year 2013
Notification
URL copied to clipboard!
Description
2,2-dimethylbutyrate (HQK-1001), an orally-bioavailable promoter-targeted fetal globin gene-inducing agent, was evaluated in an open-label, randomized dose-escalation study in 52 subjects with hemoglobin SS or S/β0 thalassemia. HQK-1001 was administered daily for 26 weeks at 30 mg/kg (n = 15), 40 mg/kg (n = 18) and 50 mg/kg (n = 19), either alone (n = 21) or with hydroxyurea (n = 31). The most common drug-related adverse events were usually mild or moderate and reversible. Gastritis was graded as severe in three subjects at 40 mg/kg and was considered the dose-limiting toxicity. Subsequently all subjects were switched to the maximum tolerated dose of 30 mg/kg. Due to early discontinuations for blood transfusions, adverse events or non-compliance, only 25 subjects (48%) completed the study. Drug plasma concentrations were sustained above targeted levels at 30 mg/kg. Increases in fetal hemoglobin (Hb F) were observed in 42 subjects (80%), and 12 (23%) had increases ≥4%. The mean increase in Hb F was 2% [95% confidence interval (CI), 0.8-3.2%] in 21 subjects receiving HQK-1001 alone and 2.7% (95% CI, 1.7-3.8%) in 31 subjects receiving HQK-1001 plus hydroxyurea. Total hemoglobin increased by a mean of 0.65 g/dL (95% CI, 0.5-1.0 g/dL), and 13 subjects (25%) had increases ≥1 g/dL. Future studies are warranted to evaluate the therapeutic potential of HQK-1001 in sickle cell disease. Am. J. Heamtol. 88:E255-E260, 2013. © 2013 Wiley Periodicals, Inc.
Authors & Co-Authors
Kutlar, Abdullah
United States, Augusta
Augusta University
Reid, Marvin E.G.
Jamaica, Kingston
The University of the West Indies
Inati, Adlette
Lebanon, Beirut
Rafik Hariri University Hospital
Taher, Ali T.
Lebanon, Beirut
American University of Beirut Medical Center
Abboud, Miguel Raul
Lebanon, Beirut
American University of Beirut Medical Center
El-Beshlawy, Amal M.
Egypt, Giza
Cairo University
Buchanan, George R.
United States, Dallas
Ut Southwestern Medical Center
Smith, Hedy P.
United States, Medford
Tufts University
Ataga, Kenneth I.
United States, Chapel Hill
The University of North Carolina at Chapel Hill
Perrine, Susan P.
United States, Boston
Boston University
Ghalie, Richard G.
United States, San Diego
Hemaquest Pharmaceuticals
Statistics
Citations: 33
Authors: 11
Affiliations: 10
Identifiers
Doi:
10.1002/ajh.23533
ISSN:
03618609
e-ISSN:
10968652
Research Areas
Genetics And Genomics
Health System And Policy